PDF《2018 第一季度报告》

2018 First Quarterly Report 第一季度报告 CHARACTERISTICS OF GEM OF THE STOCK EXCHANGE OF HONG KONG LIMITED (THE STOCK EXCHANGE ) GEM has been positioned as a market designed to accommodate small and mid-sized companies to which a higher investment risk may be attached than other companies listed on the Stock Exchange.

Prospective investors should be aware of the potential risks of investing in such companies and should make the decision to invest only after due and careful consideration. Given that the companies listed on GEM are generally small and mid- sized companies, there is a risk that securities traded on GEM may be more susceptible to high market volatility than securities traded on the Main Board and no assurance is given that there will be a liquid market in the securities traded on GEM. Hong Kong Exchanges and Clearing Limited and the Stock Exchange take no responsibility for the contents of this report, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from, or in reliance upon, the whole or any part of the contents of this report. This report, for which the directors (the Directors ) of Shenzhen Neptunus Interlong Bio-technique Company Limited (the Company ) collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM of the Stock Exchange (the GEM Listing Rules ) for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this report is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this report misleading. 香港联合交易所有限公司 ( 「联交 所」 ) GEM 的特色 GEM 的定位,乃为中小型公司提供一个上市的 市场,此等公司相比起其他在联交所上市的公司 带有较高投资风险.有意投资的人士应t解投资 於该等公司的潜在风险,并应经过审慎周详的考 虑后方可作出投资决定. 由於 GEM 上市公司普遍为中小型公司,在GEM 买卖的证券可能会较於主板买卖的证券承受较大 的市场波动风险,同时无法保证在 GEM 买卖的 证券会有高流通量的市场. 香港交易及结算所有限公司及联交所对本报告的 内容概不负责,对其准确性或完整性亦不发表任 何声明,并明确表示概不就因本报告全部或任何 部分内容而产生或因倚赖该等内容而引致的任何 损失承担任何责任. 本报告乃遵照联交所的 《GEM证券上市规则》 ( 「GEM上市规则」 ) 而刊载,旨在提供有关深圳 市海王英特龙生物技术股份有限公司 ( 「本公司」 ) 的资料.本公司董事 ( 「董事」 ) 愿就本报告的资料 共同及个别地承担全部责任.各董事在作出一切 合理查询后,确认就其所知及所信,本报告所载 资料在各重要方面均属准确完备,没有误导或欺 诈成份,且并无遗漏任何事项,足以令致本报告 或其所载任何陈述产生误导.

2 SHENZHEN NEPTUNUS INTERLONG BIO-TECHNIQUE COMPANY LIMITED FIRST QUARTERLY REPORT

2018 QUARTERLY RESULTS (UNAUDITED) The board of Directors (the Board ) of the Company is pleased to present the unaudited consolidated results of the Company and its subsidiaries (collectively the Group ) for the three months ended